Global osteoporosis drugs market is expected to reach USD 14.30 billion by 2021, growing at a CAGR of 4.0% between 2016 and 2021.
Sarasota, FL -- (SBWIRE) -- 03/09/2017 -- Zion Market Research has published a new report titled "Osteoporosis Drugs Market (Bisphosphonates, Calcitonin, Rank Ligand Inhibitors, Parathyroid Hormone Therapy (PTH) and Selective Estrogen Receptor Modulators (SERMs)) for Male and Female Population: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021". According to the report, the global osteoporosis drugs market was valued at approximately USD 11.20 billion in 2015 and is expected to reach approximately USD 14.30 billion by 2021, growing at a CAGR of around 4.0% between 2016 and 2021.
Request Free Sample Research Report @ https://www.zionmarketresearch.com/sample/osteoporosis-drugs-market
Osteoporosis is a bone disease in which a fragile bone with an increased susceptibility to fracture. Bones that commonly fracture include the backbones, the bones of the forearm, and the hip. As a result, bones become weak and may break from a fall or, in serious cases, from sneezing or minor bumps. Until a broken bone occurs there are typically no symptoms. Osteoporosis drugs are a kind of medicine for osteoporosis, such as Fosamax, Actonel, Boniva, Zoledronic Acid (Reclast or Zometa) and others.
The global osteoporosis drugs market is witnessing noteworthy growth on account of growing geriatric population coupled with changing lifestyles impinging bone health. Furthermore, increasing the prevalence of osteoporosis in postmenopausal women and increasing investment in drug discovery and development is also driving the growth of the market. Prevalence of osteoporosis is more common with age. Around 15% of white people in their 50s and 70% of those over 80 are affected by osteoporosis diseases. It is more common in women than men. However, there are different side effects and complications associated with osteoporosis drugs such as irritable bowel syndrome, heartburn, nausea, and ulcers in the stomach. Thus, side effects of osteoporosis drugs may curb the market growth in the coming years. Nevertheless, focus on R&D for advanced development of new drugs and classes is expected to help in accentuating the market growth within the forecast period.
Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/osteoporosis-drugs-market
On the basis of drug class, the market can be segmented into bisphosphonates, calcitonin, rank ligand inhibitors, parathyroid hormone therapy (PTH) and selective estrogen receptor modulators (SERMs). Bisphosphonates were the leading segment and it accounted for around 48% share of total revenue generated in 2015. Bisphosphonates are commonly prescribed the drug for treatment and prevention of osteoporosis disease. Thus, this segment is expected to show strong growth within the forecast period. Parathyroid hormone therapy (PTH) was another key segment and it is expected to witness significant growth in the near future. Development of new drug classes such as PTH and RANK ligand inhibitors are projected to propel the growth of osteoporosis drug market in the coming years. Pipeline products such as odanacatib (cathepsin K inhibitor) and romosozumab are awaiting the approval and are anticipated to drive the market growth in the years to come.
The osteoporosis drugs market is segmented on the basis of gender such as male and female. The female segment dominated the market and is expected to exhibit significant growth in the near future. There are wide discrepancies between the incidence rate in women and men. Moreover, about 90% of the hip fractures occur in people over 50 years old.
Browse detail report with in-depth TOC @ https://www.zionmarketresearch.com/report/osteoporosis-drugs-market
North America was the leading regional market for osteoporosis drugs in 2015. In terms of revenue, North America is closely followed by Europe. This growth is mainly due to the availability of the well established drug delivery system and sophisticated healthcare infrastructure. Asia Pacific is also expected to witness the fastest growth owing to increasing prevalence of osteoporosis diseased conditions, and increasing patient's awareness pertaining to bone health. Latin America and the Middle East & Africa are also expected to experience significant growth of osteoporosis drugs market in the years to come.
Some of the key participants in osteoporosis drug market are Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck & Co, Inc., Actavis plc, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. Major players are implementing sustainability strategies including product expansions, new product development and merger & acquisitions to gain the advantage over the competitors. For instance, drug maker Actavis Inc. agreed to acquire Warner Chilcott PLC for about USD 5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specialty pharmaceutical brands—and shrinking its tax burden in 2013. Pipeline drugs of Merck and Pfizer are cathepsin and aprela are projected to provide growth platform these respective companies.
Request a customized copy of report @ https://www.zionmarketresearch.com/custom/342